Increased anticoagulant activity of warfarin used in combination with doxifluridine

Masaru Nakajima, Tomoo Genda, Mayu Suehira, Hiroki Satoh, Akiko Miki, Satoko Hori, Yasufumi Sawada

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine. Methods: International normalized ratio (INR) of a 73-year-old female patient receiving warfarin was increased after starting chemotherapy using oral fluoropyrimidines (capecitabine or doxifluridine). Since the concomitant use of warfarin and the oral fluoropyrimidines was unavoidable in this case, the warfarin dosage was adjusted to keep INR within goal range (1.7-2.7). To evaluate the effects of the oral fluoropyrimidines on the anticoagulant activity of warfarin, the INR/Dose (warfarin dose in mg/day) was used. Results: To keep INR within goal range, the maintenance dosage of warfarin was reduced during the treatment with doxifluridine as well as capecitabine. It was finally reduced from 5 mg daily in the absence of oral fluoropyrimidines to 1.5 mg daily during the concomitant use of doxifluridine (600 mg daily). In contrast, the higher INR/Dose (1.03-1.66) was continued during the concomitant use of warfarin and doxifluridine compared with the INR/Dose before the start of chemotherapy (about 0.5). These results clearly indicate that the anticoagulant activity of warfarin was markedly increased by the concomitant use of doxifluridine as well as capecitabine. Conclusions: It is important that physicians closely monitor anticoagulant activity in patients concomitantly receiving doxifluridine and warfarin, and appropriately adjust the dose of warfarin.

Original languageEnglish
Pages (from-to)969-972
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume66
Issue number5
DOIs
Publication statusPublished - 2010 Oct 1
Externally publishedYes

Fingerprint

Warfarin
Anticoagulants
International Normalized Ratio
Chemotherapy
doxifluridine
Drug Therapy
Maintenance
Physicians

Keywords

  • Capecitabine
  • Doxifluridine (5′-DFUR)
  • Fluoropyrimidine Antitumor Agent
  • INR
  • Warfarin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Nakajima, M., Genda, T., Suehira, M., Satoh, H., Miki, A., Hori, S., & Sawada, Y. (2010). Increased anticoagulant activity of warfarin used in combination with doxifluridine. Cancer Chemotherapy and Pharmacology, 66(5), 969-972. https://doi.org/10.1007/s00280-010-1249-5

Increased anticoagulant activity of warfarin used in combination with doxifluridine. / Nakajima, Masaru; Genda, Tomoo; Suehira, Mayu; Satoh, Hiroki; Miki, Akiko; Hori, Satoko; Sawada, Yasufumi.

In: Cancer Chemotherapy and Pharmacology, Vol. 66, No. 5, 01.10.2010, p. 969-972.

Research output: Contribution to journalArticle

Nakajima, M, Genda, T, Suehira, M, Satoh, H, Miki, A, Hori, S & Sawada, Y 2010, 'Increased anticoagulant activity of warfarin used in combination with doxifluridine', Cancer Chemotherapy and Pharmacology, vol. 66, no. 5, pp. 969-972. https://doi.org/10.1007/s00280-010-1249-5
Nakajima, Masaru ; Genda, Tomoo ; Suehira, Mayu ; Satoh, Hiroki ; Miki, Akiko ; Hori, Satoko ; Sawada, Yasufumi. / Increased anticoagulant activity of warfarin used in combination with doxifluridine. In: Cancer Chemotherapy and Pharmacology. 2010 ; Vol. 66, No. 5. pp. 969-972.
@article{41b2621c3af7434385e7938c21835d62,
title = "Increased anticoagulant activity of warfarin used in combination with doxifluridine",
abstract = "Purpose: The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine. Methods: International normalized ratio (INR) of a 73-year-old female patient receiving warfarin was increased after starting chemotherapy using oral fluoropyrimidines (capecitabine or doxifluridine). Since the concomitant use of warfarin and the oral fluoropyrimidines was unavoidable in this case, the warfarin dosage was adjusted to keep INR within goal range (1.7-2.7). To evaluate the effects of the oral fluoropyrimidines on the anticoagulant activity of warfarin, the INR/Dose (warfarin dose in mg/day) was used. Results: To keep INR within goal range, the maintenance dosage of warfarin was reduced during the treatment with doxifluridine as well as capecitabine. It was finally reduced from 5 mg daily in the absence of oral fluoropyrimidines to 1.5 mg daily during the concomitant use of doxifluridine (600 mg daily). In contrast, the higher INR/Dose (1.03-1.66) was continued during the concomitant use of warfarin and doxifluridine compared with the INR/Dose before the start of chemotherapy (about 0.5). These results clearly indicate that the anticoagulant activity of warfarin was markedly increased by the concomitant use of doxifluridine as well as capecitabine. Conclusions: It is important that physicians closely monitor anticoagulant activity in patients concomitantly receiving doxifluridine and warfarin, and appropriately adjust the dose of warfarin.",
keywords = "Capecitabine, Doxifluridine (5′-DFUR), Fluoropyrimidine Antitumor Agent, INR, Warfarin",
author = "Masaru Nakajima and Tomoo Genda and Mayu Suehira and Hiroki Satoh and Akiko Miki and Satoko Hori and Yasufumi Sawada",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s00280-010-1249-5",
language = "English",
volume = "66",
pages = "969--972",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Increased anticoagulant activity of warfarin used in combination with doxifluridine

AU - Nakajima, Masaru

AU - Genda, Tomoo

AU - Suehira, Mayu

AU - Satoh, Hiroki

AU - Miki, Akiko

AU - Hori, Satoko

AU - Sawada, Yasufumi

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose: The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine. Methods: International normalized ratio (INR) of a 73-year-old female patient receiving warfarin was increased after starting chemotherapy using oral fluoropyrimidines (capecitabine or doxifluridine). Since the concomitant use of warfarin and the oral fluoropyrimidines was unavoidable in this case, the warfarin dosage was adjusted to keep INR within goal range (1.7-2.7). To evaluate the effects of the oral fluoropyrimidines on the anticoagulant activity of warfarin, the INR/Dose (warfarin dose in mg/day) was used. Results: To keep INR within goal range, the maintenance dosage of warfarin was reduced during the treatment with doxifluridine as well as capecitabine. It was finally reduced from 5 mg daily in the absence of oral fluoropyrimidines to 1.5 mg daily during the concomitant use of doxifluridine (600 mg daily). In contrast, the higher INR/Dose (1.03-1.66) was continued during the concomitant use of warfarin and doxifluridine compared with the INR/Dose before the start of chemotherapy (about 0.5). These results clearly indicate that the anticoagulant activity of warfarin was markedly increased by the concomitant use of doxifluridine as well as capecitabine. Conclusions: It is important that physicians closely monitor anticoagulant activity in patients concomitantly receiving doxifluridine and warfarin, and appropriately adjust the dose of warfarin.

AB - Purpose: The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine. Methods: International normalized ratio (INR) of a 73-year-old female patient receiving warfarin was increased after starting chemotherapy using oral fluoropyrimidines (capecitabine or doxifluridine). Since the concomitant use of warfarin and the oral fluoropyrimidines was unavoidable in this case, the warfarin dosage was adjusted to keep INR within goal range (1.7-2.7). To evaluate the effects of the oral fluoropyrimidines on the anticoagulant activity of warfarin, the INR/Dose (warfarin dose in mg/day) was used. Results: To keep INR within goal range, the maintenance dosage of warfarin was reduced during the treatment with doxifluridine as well as capecitabine. It was finally reduced from 5 mg daily in the absence of oral fluoropyrimidines to 1.5 mg daily during the concomitant use of doxifluridine (600 mg daily). In contrast, the higher INR/Dose (1.03-1.66) was continued during the concomitant use of warfarin and doxifluridine compared with the INR/Dose before the start of chemotherapy (about 0.5). These results clearly indicate that the anticoagulant activity of warfarin was markedly increased by the concomitant use of doxifluridine as well as capecitabine. Conclusions: It is important that physicians closely monitor anticoagulant activity in patients concomitantly receiving doxifluridine and warfarin, and appropriately adjust the dose of warfarin.

KW - Capecitabine

KW - Doxifluridine (5′-DFUR)

KW - Fluoropyrimidine Antitumor Agent

KW - INR

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=77956231596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956231596&partnerID=8YFLogxK

U2 - 10.1007/s00280-010-1249-5

DO - 10.1007/s00280-010-1249-5

M3 - Article

VL - 66

SP - 969

EP - 972

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -